Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is reason to think something is not wrong
The first announcement, in November 2020, said:
When is the merger date of MyMD & AKER? Any idea?
AKER is so small company, MyMD is a private company. Not sure why the merger is taking 3 solid months? something is not right...
Have heard nothing about that. Why would they buy or merge with a company millions of dollars in debt with no source of revenue, and in Chapter 11 bankruptcy, from which I'm told there is no recovery for a corporation.
What is interesting is the merger of AKER with MyMd Pharmaceuticals. There's real promise in that. The resulting company (finally) will be on the market as MYMD.
My understanding of all this is limited. Corrections are welcome.
This company is buying/merging with RCPIQ? What happens to the RCPIQ stocks?
I think the value of MYMD-1, and possible successors, is unrecognized, except by a few. The announcements, which only a few expect, should come as a surprise to most.
About time for MyMD Pharma to get on the stick with some announcements! They have been pretty clear that they will begin the 1st two human studies in the first quarter of 2021 utilizing MYMD-1 against depression in Covid and against Sarcopenia. Only 28 days left in the 1st quarter.
Akers Biosciences In (AKER)
3.56 ? -0.37 (-9.41%)
Volume: 681,033 @02/19/21 7:59:57 PM EST
Bid Ask Day's Range
3.52 3.56 3.48 - 3.92
AKER Detailed Quote
AKERS BIOSCIENCES INC filed this SC 13G on Feb 18, 2021
Mainfield Enterprises Inc., British Virgin Islands, owns 1,081,08 shares, which is 5.80% of the voting power.
http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-show.aspx?Type=html&FilingId=14722569&CIK=0001321834&Index=10000
Mainfield Enterprises, Inc. is a business entity registered at Global Legal Entity Identifier Foundation (GLEIF), with entity identifier is 549300AV58Y72FOPIG36. The registration start date is October 31, 2017.
No further info found.
Also, this morning, there is this form 425 SEC filing
http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-show.aspx?Type=html&FilingId=14721863&CIK=0001321834&Index=10000
Seems to document the PR released today. The content is the same.
PR this morning had immediate and temporary effect on price
https://www.businesswire.com/news/home/20210218005243/en/
Within a few minutes after the PR AKER went from $3.85 to $4.74 and immediately back to $3.85. All pre-market so looks like all on less than 20k shares traded.
Pretty strange ... and inconsequential.
AKER price: damaged by a false press release?
Akers Biosciences Responds to Erroneous Earnings Call Press Release
I doubt very much that MyVET Pharma would be associated with the Akers/MyMD Pharma relationship because of the fact that animal meds don't carry the same respectability of human meds. More likely they would be licensed to an existing veterinary pharmaceutical company in exchange for royalties.
Great find that Nemo Life Sciences and Myridine Inc. were just created this month. May have nothing to do with Akers/MyMD, but interesting non the less. Thanks for sharing.
Supera Pharmaceuticals - an interesting clue. Thanks, knuts4oe.
https://www.corporationwiki.com/p/32t1ju/supera-pharmaceuticals-inc#people
Show that on of the two "Key People" is Jonnie R. Williams. The other is the "registered agent".
What of Jonnie's is being pulled into AKER and then wrapped up in a newly emergent MYMD as it absorbs AKER and becomes the surviving listed company?
map of Jonnie R. Williams' relationships — scroll down
Note Mymd Pharmaceuticals, Inc. and Myvet Pharmaceuticals, Inc.
I wonder if AKER is going to get Myvet too? Lower regulatory if MYMD-1 were to be sold for animal use.
I, personally, am not expecting the Premas connection to amount to anything as we have heard little of any progress lately.
Interesting to note, though, that Supera Pharma and Akers Bio were talking about a merger when MyMD Pharma came on the scene. The plan now is for MyMD Pharma to buy Supera Pharma for about 43 million MyMD shares.
Premas Biotech, D-Crypt, Covid 19, Partnership with Akers
https://www.premasbiotech.com
After AKER/MyMD announced their reverse merger in November a gaggle of law firms jumped on the bandwagon to come to the rescue of AKER stockholders. I'm wondering if maybe they realized it was such a fantastic opportunity for AKER stockholders that they are now providing the share purchasing that is pushing the stock price ever higher!
Hard to believe that no one is commenting on this performance.
Diagrams: Anatabloc & MYMD-1
https://investorshub.advfn.com/uimage/uploads/2021/2/5/TZFPCZSAQCCVGBGKGY.png
Similar, but with significant differences (count carbons in rings). Biochemists, please speculate.
Oops, forgot to mention that in 2021's 1st quarter one of the studies scheduled to begin involves dosing with MYMD-1, post Covid 19 patients who have developed depression, when they previously had not had a problem with it.
Just noticed this story from Jan. 19th that the DOD has hired CRO Pharm-Olam ($36 million) to test Humira against Covid 19 as an inflammation fighter. In the Akers Biosiences Nov. 18 business report, MyMD Chief Scientific Officer, Dr. Adam Kaplan made it pretty clear that MYMD-1 was triple threat superior to Humira in inflammation reduction, anti-depression, and maintenance of immune system.
https://ih.advfn.com/stock-market/stock-news/84120896/us-department-of-defense-selects-pharm-olam-as-cro
Comments welcomed.
$2.85 NICER
Have totally failed to get my head around what they are proposing in this filing with the SEC.
My first reaction, though, is that this filing was known to the insiders ahead of time, and the stock had a great week. I take this as a good sign.
I've been telling the RCPIQ board about the AKER board but so far no evidence of a migration.
That's how I've seen it. That 20% may return revenue dwarfing anything else they might have done.
Can't say this is much of a message board, especially since AKER put in quite an impressive performance this week given there was no news to support it. Perhaps the flood of lawyers pursuing AKER for what they think was the lousy deal (80%/20% ownership), discovered that AKER was getting 20% of what may become a mind blowing pharmaceutical powerhouse, and decided to buy into it instead.
Looks different to me. I don't recall seeing "Vaccine" prominently featured.
Is this a new Akers Biosciences website
http://www.akersbio.com/
Akers Biosciences - patent news: regulating tumor necrosis factor-alpha
From the November Akers presentation
The presentation is at:
https://www.webcaster4.com/Player/Index?webcastId=38815&g=b4677770-9693-447f-9869-a4ac2adbc147
Adam Kaplan's part of the presentation is especially informative. It starts at minute 10.
Dr Adam Kaplan, who earlier in December officially became the Chief Scientific Officer at MyMD Pharmaceuticals, did an excellent job of detailing the significant advantages of dosing with MYMD-1, in the "Akers Biosciences Business Update".
He points out that it is an excellent selective TNFa blocker which makes it a formidable competetor in the $40 billion market for Humira and other TNFa blockers.
It is also an excellent anti-inflammitory which should be useful in treating any disease or medical condition whose name ends in "itis".
It is also a potent anti-depressant which would have application in countless medical conditions.
All of this comes to the Akers/MyMD merger from MyMD. Akers brings only its questionable relationship with Premas for a vaccine, and its ability to raise funds for MyMD. Thus its 20% share in the final MyMD Pharmaceuticals.
Taming the adverse effects of excessive NF-kB
From the paper linked by power walker: "Anatabine ameliorates intestinal inflammation and reduces the production of pro-inflammatory factors in a dextran sulfate sodium mouse model of colitis"
https://journal-inflammation.biomedcentral.com/articles/10.1186/s12950-020-00260-6"
Extremely interesting!
I just sent this info to a very capable and unconventional doctor:
Thanks for posting. Looks like competition heating up for MyMD Pharma/Johns Hopkins. Wonder what the patent situation is!
leif and knuts, FWIW - found this article when looking for info on Crohn's Disease and Anatabloc. May be tied into Philip Morris IP on anatabine. Link to full report is on the right side of the page.
https://www.pmiscience.com/library/publication/Anatabine-ameliorates-intestinal-inflammation
leifsmith
I have long been aware of the huge pharma forces who want to see MyMD Pharma fail. It is because of this, that as we approach phase 2 human trials, I would like to see MyMD adopt a licensing and royalty approach, whereby any successful phase 2 human study would be licensed to an appropriate international pharmaceutical company for the required phase 3 human study. This would pass on the huge expense of phase 3 studies to companies that can afford it, while making them partners in this new field of medical science.
"FDA is fully informed of the significance of the MYMD-1 molecule and will likely fast track it."
This would have to be an FDA devoted more to public health than to serving large drug manufacturers. I hope you are right. The MYMD-1 molecule may threaten the sales of many expensive drugs.
To be clear, I am sure there are many people working for the FDA whose objective is genuinely public health.
About your statement "Given the ways of the FDA it may be years before those suffering the effects of chronic inflammation can obtain relief again", I have come to believe that the FDA is fully informed of the significance of the MYMD-1 molecule and will likely fast track it. Only time will tell.
On another note, your mention of izof-texas (eyes of Texas), made me smile as I have been trying to remember his name. He was a big contributor to the anatabine story.
Looks like AKER has broken out of its trading range of 1.95 to 2.05 on no news at a time of year where tax selling pressure usually predominates. Best of luck to all who have a piece of Akers' Biosciences!
Anatabine, possibly MYMD-1, and Chron's disease
This is an excerpt from an old post by izof_texas on a now extinct board, CIGX_VIPGROUP on Yahoo, probably Dec 2014, about the alkaloid based molecule anatabine citrate, and Chron's Disease:
Dr. Patrizio P. Caturegli, Johns Hopkins University School of Medicine takes Jonnie Williams' discovery seriously.
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
Created
|
01/15/15
|
Type
|
Free
|
Moderators |
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
Shs Outstand | 8.72M
|
Insider Trans | -0.83%
|
Book/sh | 2.96 |
Cash/sh | 2.00 |
Debt/Eq NO DEBT | 0.00 |
52W Range | 1.55 - 12.72 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |